After surveying 50 physicians regarding Vascepa, Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Amarin with a $35 price target. The stock closed yesterday up 48c to $16.94. The analyst says the survey results underscore her belief that the market opportunity is underappreciated. 52% of physicians noted the high triglyceride patients they see have cardiovascular risk factors beyond what can be mitigated by cholesterol management, Chen tells investors in a research note. She believes the Reduce-It study positions Vascepa to be the first drug to cost-effectively help address CV risk beyond cholesterol management. Chen expects an acceleration in the uptake of Vascepa in 2019.